Granted Patent B2

US 12,528,803 · App. 17/967,346 · Granted Jan 20, 2026

Inventors: Bryce A. Harrison (Framingham, MA); James E. Dowling (Lexington, MA); Aleksey I. Gerasyuto (Flemington, NJ); Matthew G. Bursavich (Needham, MA); Dawn M. Troast (Bedford, MA); Blaise S. Lippa (Newton, MA); Bruce N. Rogers (Belmont, MA); Cheng Zhong (Belmont, MA); Fu-Yang Lin (Sudbury, MA); Brian Sosa (Cambridge, MA); Andrea Bortolato (Metuchen, NJ); Mats A. Svensson (New York, NY); Eugene Hickey (Danbury, CT); Kyle D. Konze (Katonah, NY); Tyler Day (New York, NY); Byungchan Kim (West New York, NJ)

Assignee: Morphic Therapeutic, Inc.

C07D471/04A61K9/0053C07D519/00

Abstract

Claims (36)

1 . A compound of formula (I):

A-B—C  (I)

wherein:

A is

B is -alkylene-C*H(F)—, -alkylene-C*(F) 2 —, -alkylene-CH(F)C*H 2 —, or -alkylene-C(F) 2 C*H 2 —;

C is

R 1 , in each instance, is independently H, alkyl, or alkoxy;

R 2 is substituted or unsubstituted aryl;

R 3 is H,

R a is H or (C 1 -C 6 )alkyl;

n is 0, 1, 2, 3, or 4;

* denotes the point of attachment of B to C; and

the absolute configuration at any stereocenter is R, S, or a mixture thereof;

or a pharmaceutically acceptable salt thereof.

2 . The compound of claim 1 , wherein R a is H.

3 . The compound of claim 1 , wherein the at least one instance of R 1 is OMe.

4 . The compound of claim 1 , wherein all instances of R 1 are H.

5 . The compound of claim 1 , wherein R 2 is unsubstituted aryl.

6 . The compound of claim 1 , wherein R 2 is substituted aryl.

7 . The compound of claim 6 , wherein R 2 is substituted with one or more substituents independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, alkoxy, OH, halide, —(O)alkyl, -alkylene-heteroaryl, -alkylene-O-alkyl; -alkylene-O-cycloalkyl, alkylene-O-heterocyclocycloalkyl, —O-alkylene-cycloalkyl, —O-alkylene-heterocycloalkyl, and each of which can be further substituted with alkyl, halogen, and alkoxyl.

8 . The compound of claim 1 , wherein B is —(CH 2 ) 4 C*H(F)— or —(CH 2 ) 4 C*(F) 2 —.

9 . The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

10 . The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

11 . The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

12 . The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

13 . The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

14 . The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

15 . The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

16 . A pharmaceutical composition, comprising a compound of claim 1 ; and a pharmaceutically acceptable excipient.

Assignments (4)

Continuity (5)

References Cited (234)